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Introduction: Introducing biosimilar infliximab for the treatment in rheumatology
(rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn’s
disease and ulcerative colitis) may reduce treatment costs associated with biologics.
This study aimed to investigate the budget impact of adopting biosimilar infliximab in
five European countries, considering that the budget impact includes the adoption of
biosimilar infliximab and the availability of biologic alternatives such as vedolizumab,
biosimilar etanercept, biosimilar rituximab, and other relevant factors.
Methods: An existing budget impact model was adapted to forecast the budget
impact in the UK, Germany, France, Spain, and Italy. Epidemiological parameters
were derived from published literature reviewed in July 2015. Current market shares
of biologics were derived from Therapy Watch (2012/2013 data). Respondents in a
Delphi panel, conducted in 2015 and consisting of several leading rheumatologists
and gastroenterologists from different nationalities, were asked to forecast uptake of
biosimilar infliximab and estimate the proportion of patients eligible for a particular type
of biological treatment, including biosimilar infliximab. Scenario analyses assessed the
influence of various factors, including price reductions, on the budget.
Results: Uptake of biosimilar infliximab was particularly expected for naïve patients;
switching patients that already received other biologics was not expected much. Market
shares after 5 years of biosimilar infliximab were∼2% in rheumatology in all five countries
and in gastroenterology ranged from 4% in France to over 30% in Italy. Except for France,
budgets were expected to decrease for rheumatologic diseases. For gastroenterology,
budgets were expected to decrease in Spain and Italy. Budgets were expected to
increase substantially in the UK and Germany, due to the introduction of vedolizumab
in the studied period. In France, budget was expected to slightly increase for ankylosing
spondylitis, Crohn’s Disease, and ulcerative collitis. Savings in budget were expected in all
countries, for all diseases, when larger price discounts on biosimilar infliximab were used.
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Discussion andConclusion: This study has shown that only when price reductions are
large enough (i.e., 50% or more), physicians indicated that they will prescribe biosimilars.
Policy makers should ensure substantial price reductions and stimulate physicians to use
biosimilar products, to obtain savings in healthcare budgets.
Keywords: budget impact, biosimilars, infliximab, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel
disease
INTRODUCTION
Biological drugs acting as anti-tumor necrosis factors (TNF),
inhibitors of the T- and B-cell costimulation, and inhibitors
of the interleukin (IL)-6 and the IL-1 have been shown
to successfully reach treatment targets (e.g., remission, low
disease activity) and improve patients’ quality of life for several
gastrointestinal and rheumatic diseases in a number of clinical
situations (Mathias et al., 2000; Dignass et al., 2010, 2012;
Lichtiger et al., 2010; Braun et al., 2011; Smolen et al.,
2014). Both knowledge and experience gained with these drugs
have supported their acceptance by gastroenterologists and
rheumatologists, and the drugs’ integration in the treatment
algorithms of inflammatory bowel disease (IBD), including
Crohn’s disease (CD) and ulcerative colitis (UC)—together
also named gastroenterological indications, rheumatoid arthritis
(RA), and ankylosing spondylitis (AS)—together also named
rheumatological indications (Dignass et al., 2010, 2012; Braun
et al., 2011; Smolen et al., 2014).
Treatment with biological drugs in RA, AS, CD, and UC is
considered highly effective, but often comes at a high cost. In the
EuropeanUnion Five (EU5)markets including France, Germany,
Italy, Spain, and the United Kingdom, annual biological drug
acquisition costs in RA range from e6,650 per patient (B cell
costimulation inhibitor rituximab in Italy) toe23,395 per patient
(T cell costimulation inhibitor abatacept in Germany) assuming
list prices and use at the label dose (Italian hospital pharmacist,
2012; Rote Liste, 2013). Notably, acquisition cost of a specific
biological drug may vary across indications due to different
dosing regimens, but it always outweighs the cost of conventional
non-biologic treatment. Several cost-of-illness studies for RA
found that the cost of anti-TNF drugs comprised more than
double the total medication expenditure, and was the main
contributor to the healthcare outpatient costs (Michaud et al.,
2003; Fautrel et al., 2005; Verstappen et al., 2005; Li et al., 2006).
Likewise, a cost study in the UK also showed the increased
medication costs as a proportion of total costs in AS (Cooksey
et al., 2015). Similarly, in a cost study of IBD in the Dutch setting,
the cost of anti-TNF drugs was estimated to account for 64 and
54% of the total healthcare costs of CD and UC, respectively (van
der Valk et al., 2014).
The recent introduction of biosimilar infliximab (marketed
as Inflectra R© and Remsima R©), an anti-TNF biologic indicated
for RA, AS, CD, and UC among other conditions, to the EU
markets, may address this issue of increasing financial impact of
treatment with biologics. Namely, biosimilar infliximab gained
market authorization by the European Medicines Agency (EMA)
for the same indications as the reference biologic, but is available
at a (up to 25%) lower price in the EU5. However, various
factors may influence the adoption of biosimilar infliximab
by various stakeholders (e.g., clinicians, payers, patients) and,
therefore, its possible impact on healthcare budgets (Moors,
2007). Local costs of biologics, reimbursement policies and
budgets, differences in medical practices are some of the factors
that may influence patient’s access to biological drugs, both
brands and biosimilars, and their adoption (Kobelt and Kasteng,
2009; Hockley et al., 2012; Rencz et al., 2015). For clinicians to
integrate biosimilar infliximab in treatment algorithms, factors
such as the availability of clinical trial evidence and comparability
with the reference drug may be of key importance. In particular,
biosimilar infliximab was authorized by EMA based on evidence
from extensive comparability exercises in quality, safety and
effectiveness characteristics to the reference drug, and evidence
from clinical trials in patients with AS (PLANETAS) and
in patients with RA (PLANETRA). Thus, the adoption of
biosimilar infliximab for use in extrapolated indications, CD
and UC, may be particularly limited, judging by the initial
recommendations proposed by the European Crohn’s and Colitis
Organization in 2013 (ECCO; Danese and Gomollon, 2013).
Their recommendations urge for clinical evidence in patients
with CD and UC, and discourage switching from an established
biologic to a biosimilar for reasons other than efficacy and
safety. Furthermore, the adoption of biosimilar infliximab for
RA, AS, CD, and UC at European markets, may be additionally
challenged by future dynamics in biological drugs markets
involving the availability of a new biological brand for the
treatment of IBD, vedolizumab, and possible future introductions
of biosimilars of etanercept and rituximab indicated for RA
and AS.
The aim of this study is to calculate the impact of adopting
biosimilar infliximab for the treatment of RA, AS, CD, and
UC on the healthcare budgets in the EU5, taking into account
that the budgetary impact is not limited to the adoption of
biosimilar infliximab, but also needs to reflect the availability of
biologic alternatives such as vedolizumab, biosimilar etanercept
and biosimilar rituximab, and other relevant factors.
MATERIALS AND METHODS
A budget impact analysis (BIA) was performed to compare
the “world with biosimilar infliximab” to the “world without
biosimilar infliximab” for treatment of RA, AS, CD, andUC in the
EU5. The budget impact of treatment with biosimilar infliximab
was assessed each year up to 5 years, from the perspective of
a healthcare payer (so not including costs in other sectors e.g.,
productivity costs).
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Adoption of Biosimilar Infliximab (Future
Market Shares)—Delphi Survey
A two-round Delphi survey was conducted with rheumatology
and gastroenterology experts from the EU5 to establish some
of the factors influencing adoption of biosimilar infliximab and
the corresponding parameter estimates for market shares of
biosimilar infliximab for treatment of RA, AS, CD, and UC in
the next 5 years.
Clinicians were considered eligible for our study if they: (1)
were appraised as local/international experts in their field, (2)
are actively involved in treating or supervising the treatment of
patients with RA and AS/CD and UC. Additionally, clinicians
involved in forming national/international treatment guidelines
were preferred. To identify potential participants, MEDLINE
was searched for recent publications in rheumatology and
gastroenterology concerning treatment recommendations on
biologics use in RA, AS, CD, and UC. Additionally, medical
directors of Hospira were asked to nominate local clinical experts.
An information letter was sent to physicians setting out the
aims of the study and explaining the nature of their contribution.
No informed consent from physicians was needed as data were
collected and analyzed anonymously. Physicians received a fee
for participation in the study. Given that the Delphi survey did
not collect health data and did not gather data from patients, no
approval from an ethics committee was required as set out in the
Belgian law of 7th May 2004.
A total of 106 rheumatology and gastroenterology experts
from the EU5 were invited to participate. Each expert received
a field—(i.e., rheumatology and gastroenterology) and country—
specific survey. In the first survey, participants were asked to
reflect in their answers a general attitude and expectations of
clinicians in their own country for the adoption of Infliximab
biosimilars. Importantly, data from gastroenterology surveys
were pooled per each country, while all the response data from
the rheumatology field surveys were pooled together because
fewer rheumatologists participated in the survey.
In the second round, respondents from the first round
received personalized surveys that contained their initial answer
and summarized responses from the first round. Here, experts
were given the opportunity to change their initial answer in light
of other experts’ responses.
The surveys examined a number of medical practice related
issues that may aid in explaining the expected adoption of
biosimilar infliximab, in particular: (1) the number of patients
in their institution that are eligible and receiving biologic drugs,
(2) reasons for limited access to biological drugs, (3) the role
of patients’ preferences in biologic treatment choice and rank
order of biologics, (4) the general attitude of rheumatologists and
gastroenterologists toward the use of biosimilar infliximab in RA,
AS, CD, and UC, (5) the expectation of any physician incentives
(e.g., prescription quotas, prescription conditions/guidelines,
official recommendations on switching, etc.) to prescribe
biosimilars infliximab.
The general attitude of rheumatologists and
gastroenterologists toward the use of biosimilar Infliximab
in RA, AS, CD, and UC, was assessed by comparing the level
of comparability of the efficacy and safety profile of biosimilar
Infliximab to the one of the reference biologic. Here, levels of
comparability considerations were measured on a 5-point Likert
scale, ranging from “1” (considered not comparable) to “5”
(considered comparable). To indicate the patients’ preferences
in biologic treatment choice, experts were asked to rank the
available drugs from the most to least likely to be chosen by
patient. Other survey questions included (e.g., on the future
market shares of biosimilar infliximab) were designed to capture
estimates on scale 0–100% and were generally stratified by
indication (i.e., RA, AS, CD, and UC) and previous use of
biological drugs (i.e., use in naïve and existing patients).
Model Structure
An unpublished budget impact model as developed by WG
Consulting Healthcare Limited for Hospira was modified and
updated to include all currently available biological drugs in
the EU5 for treatment of RA, AS, CD, and UC. This model is
informedwith country-specific epidemiological data, current and
future market shares of each biological drug, and direct treatment
cost data (see further for data sources). Patient population in
the model comprises all patients who are eligible and receive
biological drugs for RA, AS, CD, and UC in practice (see further
for data sources). Both biologic naïve and existing patients were
included.
In the base-case analysis, in the “world with biosimilar
infliximab” scenario, existing patients who enter the model may
stay on their initial biologic therapy or switch to biosimilar
infliximab, while naïve patients may be allocated to any of
the already available biological drugs including biosimilar
infliximab. For treatment of AS, biological drugs considered
were: etanercept, adalimumab, golimumab, infliximab. Next to
the aforementioned biologics, treatment of RA also considered
certolizumab, rituximab, abatacept, and tocilizumab. For
treatment of CD, adalimumab and infliximab were considered,
while the treatment of UC considered golimumab, adalimumab,
and infliximab. Importantly, next to biosimilar infliximab, a
novel treatment alternative considered for treatment of CD and
UC was a new biological brand vedolizumab authorized by EMA
in 2014. At the time of conducting this study, vedolizumab has
only been available in the UK and Germany. Thus, in those two
markets, both existing and naïve CD and UC patients who enter
the model could receive vedolizumab as a treatment alternative
in the base case. After each model cycle, existing patients were
assumed to continue treatment with the biological drug assigned
in the previous model cycle.
In the “world without biosimilar infliximab” scenario, both
naïve and existing patients who enter the model were allocated
to currently available biological drugs according to their market
shares. In our study, treatment discontinuation and all-cause
mortality were neglected. The model provided yearly budget
impact estimates. The time horizon of the model was 5 years. The
model was developed in MS Excel.
Epidemiological Data
Data on country-specific incidence and prevalence rates were
derived from the published literature. We reviewed the literature
for relevant publications up until July 2015. Data on the
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percentage of patients who are eligible and receive biological
drugs in practice were based on the experts’ opinion assessed in
our Delphi survey. The number of patients in each yearly model
cycle was adjusted for the country-specific population growth
rate.
Current Market Shares of Biological Drugs
Current market shares of biological drugs available in the
EU5 for RA, AS, CD, and UC were based on data obtained
from Therapy Watch, Research Partnership Ltd (2012 and
2013 data; https://www.researchpartnership.com/what-we-do/
syndicated/therapywatch/). Therapy Watch presents an online
patient tracking tool that collects real-time information from a
panel of specialists recruited to enter online patient record forms
via a secure physician website.
Cost Data
Three types of costs directly related to treatment were included
in this BIA: annual acquisition costs, administration costs, and
therapy monitoring costs. To calculate the annual acquisition
costs, official national list prices and use at the label dose were
assumed. Price discounts on biosimilar infliximab compared to
reference infliximab varied between countries and were (in 2015)
10% in the UK, 14% in Germany, 0% in France, 18% in Spain,
and 25% in Italy. These discounts were based on list prices of
drugs as provided by national agencies at the moment of data
search. The annual acquisition costs assumed no vial sharing.
Finally, a distinction was made between the costs occurring in the
first year of initiating biologic treatment (induction treatment)
and subsequent years (maintenance treatment), as for some
treatments (e.g., infliximab, abatacept) dosing differs between
induction treatment and maintenance treatment.
For calculating the annual costs of administration and
treatment monitoring, national tariffs or cost and recourse
use data collected from published literature were used. All
costs were inflated to 2014 levels using the harmonized
index for consumer product (HICP) for the health sector
separately for each country1. For comparability, costs for
the UK were expressed in Euro values, using a exchange
rate of £1 = e1.36 (http://www.xe.com/currencyconverter/
convert/?From=GBP&To=EUR; 06/09/2015). Costs were not
discounted as recommended by the International Society for
Pharmacoeconomics and Outcomes Research for BIAs (ISPOR)
Task Force (Mauskopf et al., 2007).
Scenario Analyses
To examine the impact of factors influencing adoption of
biosimilar infliximab on the budget, six scenario analyses were
conducted. The first scenario assumed biosimilar infliximab
would be available at a discount of 50% compared to the
reference biologic. The second scenario assumed the availability
1Data Market. HICP (2005 = 100) - Annual Data (Average Index and Rate of





of biosimilar infliximab at a discount of 75% compared to the
reference biologic. The third scenario assumed the availability
of clinical trial/observational study evidence confirming the
efficacy and safety of biosimilar infliximab in extrapolated
indications, CD, and UC. The fourth scenario examined the
budget impact of adoption of biosimilar infliximab in Italy, Spain,
and France, conditional on the availability of a new biological
brand vedolizumab for treatment of CD and UC. Here, the
price of vedolizumab was assumed to be the average of prices
in the UK (i.e., £2,050) and Germany (i.e., e4,305.60). Similarly,
scenarios 5 and 6 examined the budget impact of adoption of
biosimilar infliximab conditional on the future availability of
biosimilar etanercept for treatment of RA and AS, and biosimilar
rituximab for treatment of RA, respectively. In the EU5 markets,
biosimilar etanercept and rituximab were assumed to be available
at the same discounts compared to their reference drugs as
currently is established for biosimilar infliximab. Here, after
the first year (from year 2016 onwards), existing patients could
switch from their initially assigned biologic therapy to biosimilar
etanercept (scenario 5) or biosimilar rituximab (scenario 6) while
naïve patients may be allocated to any of the already available




A total of 106 rheumatology and gastroenterology experts from
the EU5 were invited to participate in our Delphi survey. Thirty-
five (response rate 33%) and seventeen (response rate 17%)
experts responded to the first and second round of survey,
respectively. Respondent demographics are displayed in Table 1.
Respondents believed that efficacy of biosimilar infliximab
was comparable to reference infliximab in both rheumatology
and gastroenterology; on a scale of 1 (not comparable) to 5
(comparable) median responses were 4 or 5 for all countries in
both rheumatology and gastroenterology. Likewise, they believed
that safety profile was comparable. Comorbidities were most
often mentioned as a reason not to use biologics in treating RA
and AS patients that were considered eligible for treatment with
biologics. Patient characteristics and patient preferences were
other reasons for not using biologics. In CD and UC, patient
preferences were most often the reason not to use biologics. In
these patients, comorbidities were another reasons not to use
biologics. Table 2 provides the development of the number of
patients that were considered eligible for treatment with biologics
in the five countries over the study period.
Market Shares
Figures 1–5 provide the market shares of the various biologics
over the studied period in the EU5. For all countries, the uptake
of biosimilar infliximab was smaller for RA and AS than for CD
and UC. In all countries and for all four diseases, the market
share of biosimilar infliximab increased over time. The increasing
market share of biosimilar infliximab is also shown in Table 3.
For RA, physicians in all five countries indicated that 0% of
existing patients would switch to biosimilar infliximab. Only 5%
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Working setting University hospital = 23 University hospital = 7
Specialized hospital = 1 Specialized hospital = 1




Years in clinical practice Mean = 15, range 4–32 Mean = 22, range 12–35
Number of treated
patients/whose treatment
is supervised per month
Mean = 185, range
15–1,500
Mean = 146, range
25–300
Disease severity of treated
patients
Moderate = 28% Moderate = 40%
Severe = 19% Severe = 27%
of existing AS patients would switch from reference infliximab
to biosimilar infliximab. For existing CD (EU5 average 9.5%)
and UC (EU5 average 8.7) patients, the share was higher, but
still limited. These rates varied substantially between countries,
ranging from 0% in France and Spain to 20% in Italy. On average,
2% of CD and UC patients treated with adalimumab would
switch to biosimilar infliximab, and 2% of UC patients would
switch from golimumab to biosimilar infliximab. Figures 1, 2
further show that a large proportion of CD and UC patients
would switch to vedoluzimab in UK and Germany, in addition
to the patients that were treated with biosimilar infliximab.
For all four diseases studied, increasing market shares of
biosimilar infliximab was mainly driven by naïve patients, which
is shown in the lower part of Table 3. For RA, an increasing
share of naïve patients would be prescribed biosimilar infliximab
over time, reaching 16% in year 5. In the UK, Italy and Spain,
more than half of the naïve IBD patients would be treated with
biosimilar infliximab from year 3 onwards.
Budget Impact
Figure 6 shows that, except for France, spending for
rheumatology (RA plus AS) for year 5 decreased with the
introduction of biosimilar infliximab in the base case analyses. In
France, the budget increased by adopting biosimilar infliximab.
In UK, Germany, Spain, and Italy, savings were obtained from
the introduction of biosimilar infliximab in RA in year 5. In
France, the budget was virtually unaffected for RA. For AS
biosimilar infliximab resulted to a budget savings in Germany,
Spain, and Italy, and increased spending in UK and France.
Figure 7 shows that the budget for gastroenterology (CD plus
UC) decreased only for Spain and Italy compared to a situation
without biosimilar infliximab in the base case analyses. Adopting
biosimilar infliximab in UK, Germany and (to a lesser extent)
TABLE 2 | Number of patients eligible for treatment with biologics.
Year 0 Year 1 Year 2 Year 3 Year 4 Year 5
RHEUMATOLOGY
UK 63,270 63,694 64,101 64,491 64,867 65,227
Germany 62,899 63,050 63,195 63,334 63,468 63,596
France 34,874 35,058 35,238 35,411 35,580 35,743
Spain 45,735 45,625 45,519 45,415 45,315 45,217
Italy 60,698 60,995 61,286 61,571 61,850 62,122
GASTROENTEROLOGY
UK 63,271 63,695 64,106 64,504 64,889 65,263
Germany 27,060 27,125 27,182 27,233 27,279 27,319
France 35,896 36,087 36,267 36,437 36,597 36,749
Spain 11,251 11,224 11,198 11,174 11,151 11,129
Italy 4,079 4,099 4,117 4,133 4,147 4,160
France, showed to increase the budget throughout the 5 year
study period. It should be noted that for UK and Germany,
these analyses include the adoption of vedulizumab, which had
a large effect on the total budget spent on biologicals. These
patterns were present for both CD and UC. The increasing
budget was particularly prominent in the UK with additional
expenditures of e65 million (almost £50 million) in year 5 and
e15 million in Germany. Budgets in UK and Germany grew
mostly in the first 2 years, after which growth flattened. This was
caused by a stabilization in the percentage of patients that shifted
to biosimilar infliximab.
The budgetary effect of introducing biosimilar infliximab was
larger in gastroenterology than in rheumatology.
Scenario Analyses
Various scenario analyses were performed to examine the
influence of specific factors on the budget impact of biosimilar
infliximab. The results of the scenario analyses are presented
in Table 4. Firstly, the price discount of biosimilar infliximab
relative to reference infliximab was varied. If the price of
biosimilar infliximab was set at 50% of reference infliximab,
adopting biosimilar infliximab decreased the budget in
all countries. In rheumatology, budget savings in year 5
varied from e22 million (France) to e81 million (Italy);
in gastroenterology savings varied from e12 million (Italy)
to almost e250 million (£181 million) in the UK. This
was particularly due to the higher proportion of patients
that were to be switched from existing reference infliximab
to biosimilar infliximab. In addition, the proportion of
naïve patients to receive biosimilar infliximab increased. If
the price of biosimilar infliximab was set at 75% discount
from the reference product (scenario 2), savings were even
higher. In rheumatology, savings ranged from e66 million
(France) to e289 million (Germany); and from e24 million
(Italy) to almost e340 million (£249 million) in UK for
gastroenterology.
At the moment of study, evidence for the safety and
effectiveness of biosimilar infliximab is currently limited to
RA and AS. The third scenario assessed the budget impact
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FIGURE 1 | Market shares biologics UK in years 0–5.
FIGURE 2 | Market shares biologics Germany in years 0–5.
if additional evidence would be available for CD and UC.
Compared to the base case, savings in Italy and Spain were larger
in this scenario. In the UK, the budgetary impact of adopting
biosimilar infliximab was smaller than in the base case, but still
the budget was higher than the situation without biosimilar
infliximab. In France, spending would increase compared to the
base case. In Germany, additional evidence would increase the
budget in the first years, but lead to savings in years 4 and 5,
compared to the base case.
Vedoluzimab was, at the moment the study was performed,
only available in UK and Germany (and as such was
included in the base case analyses for those countries).
Scenario 4 investigated the budget impact if vedoluzimab
would also available in the other countries. For all three
countries, the introduction of vedoluzimab would lead
to an increase in spending compared to the base case.
The increase in budget due to vedolizumab was largest
in France. This resembles the large budgetary impact of
Frontiers in Pharmacology | www.frontiersin.org 6 May 2017 | Volume 8 | Article 322
Kanters et al. Budget Impact of Biosimilar Infliximab
FIGURE 3 | Market shares biologics France in years 0–5.
FIGURE 4 | Market shares biologics Spain in years 0–5.
vedolizumab in UK and Germany as shown in the base case
analyses.
Scenarios 5 and 6 assessed the budget impact of introducing
biosimilar etanercept for RA and AS (scenario 5) and
biosimilar rituximab for RA only (scenario 6), in addition
to biosimilar infliximab. In all countries, scenarios 5 and
6 led to savings in year 5 compared to a situation without
biosimilars (except for France in situation 6). The savings
of introducing biosimilar etanercept (scenario 5) were
largest in Germany and Italy. Likewise, the savings of
introducing biosimilar rituximab (scenario 6) was largest in
Germany.
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FIGURE 5 | Market shares biologics Italy in years 0–5.
DISCUSSION
This study assessed the budget impact of adopting biosimilar
infliximab for RA, AS, CD, and UC in the EU5, using specialist
assumptions derived from a Delphi survey performed in 2015.
To the best of the authors’ knowledge, this is the first study that
calculates the budget impact taking into account the adoption of
biosimilar infliximab and the availability of biologic alternatives
such as vedolizumab, biosimilar etanercept, and biosimilar
rituximab. The study showed that the budgetary impact of
introducing biosimilar infliximab varied between countries and
between diseases.
In RA, savings would occur in all countries but France,
where budget was unaffected by the introduction of biosimilar
infliximab. In AS, savings would occur in Germany, Spain,
and Italy; in the UK and France budget would increase by
introducing biosimilar infliximab. Biosimilar infliximab is used
in naïve patients, whereas these patients would have been mostly
prescribed reference infliximab if biosimilar infliximab would
not be available. As reference infliximab is more expensive, this
results in an overall decrease in budget. If savings on budget due
to biosimilar infliximab in RA and AS were observed, these were
limited in size, as the proportion naïve RA patients to receive
biosimilar infliximab was only 5% and the proportion of naïve
AS patients to receive biosimilar infliximab was 28% in year
5 (using the current price discounts). For both rheumatologic
diseases, (virtually) no patients would switch from other biologics
treatment to biosimilar infliximab.
The proportion of IBD patients treated with biosimilar
infliximab was much larger than the proportion of RA patients
treated with infliximab. For CD and UC, 20% of French
naïve patients, 35% of German naïve patients and more than
half of the naïve patients in UK, Italy, and Spain received
biosimilar infliximab in year 5. Only a small proportion of
existing IBD patients would switch, similar to the situation for
RA and AS patients. For gastroenterology, adopting biosimilar
infliximab would lead to savings in Spain and Italy, in which
substantial price reductions were used. In contrast, a substantial
increase in the budget in UK and Germany was shown. For
these countries, the analyses not only include the adoption of
biosimilar infliximab, but also the introduction of vedoluzimab.
Vedolizumab is priced higher than existing treatments. Despite
the higher price, many CD and UC patients are switched to
vedolizumab, reaching a market share of∼15% in year 5 in these
two countries. As a result, the budget increased in these two
countries.
For France, the budget slightly increased with the introduction
of biosimilar infliximab for AS, CD, and UC; the budget
for RA was almost equal in the situations with and without
biosimilar infliximab. Similarly, budget for AS increased in the
UK with the introduction of biosimilar infliximab. Biosimilar
infliximab reduced the market share of reference infliximab, but
also reduced the market shares of other biologics (etanercept
and adalimumab). As total costs for biosimilar infliximab were
higher than total costs for etanercept and adalimumab, the
budget increased with the introduction of biosimilar infliximab.
Theoretically, the introduction of biosimilar infliximab should
have no effect on budget in France, as biosimilar infliximab is not
superior to reference infliximab in terms of effects or costs, and
pateints are therefore not expected to switch. This was observed
only for RA. However, for France, the model showed that the
budget would increase in AS, CD, and UC. This implies that
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TABLE 3 | Proportion of patients receiving biosimilar infliximab (year 0 = 2015).
Year 0 Year 1 Year 2 Year 3 Year 4 Year 5
PROPORTION OF TOTAL PATIENTS RECEIVING BIOSIMILAR INFLIXIMAB
Rheumatology
UK (%) 0.0 0.5 0.8 1.0 1.4 1.8
Germany (%) 0.0 0.7 1.0 1.2 1.5 1.9
France (%) 0.0 0.8 1.0 1.3 1.7 2.3
Spain (%) 0.0 0.7 0.9 1.0 1.4 1.8
Italy (%) 0.0 1.2 1.4 1.5 1.8 2.2
Gastroenterology
UK (%) 0.0 5.7 7.4 9.2 11.0 12.7
Germany (%) 0.0 11.9 11.2 13.4 16.0 18.4
France (%) 0.0 0.6 1.5 2.3 3.0 4.0
Spain (%) 0.0 2.3 5.0 7.7 10.4 13.1
Italy (%) 0.0 16.8 20.2 24.5 28.7 32.9
PROPORTION OF NAÏVE PATIENTS RECEIVING BIOSIMILAR INFLIXIMAB
Rheumatology
UK (%) 0.0 7.5 7.5 7.0 12.5 16.3
Germany (%) 0.0 7.5 7.5 7.0 12.5 16.3
France (%) 0.0 7.5 7.5 7.0 12.5 16.3
Spain (%) 0.0 7.5 7.5 7.0 12.5 16.3
Italy (%) 0.0 7.5 7.5 7.0 12.5 16.3
Gastroenterology
UK (%) 0.0 30.0 51.3 53.8 56.3 56.3
Germany (%) 0.0 10.0 10.0 30.0 35.0 35.0
France (%) 0.0 10.0 15.0 15.0 15.0 20.0
Spain (%) 0.0 50.0 60.0 62.5 65.0 67.5
Italy (%) 0.0 50.0 47.5 60.0 65.0 70.0
physicians might have information on additional price discounts
of biosimilar infliximab or that they are expecting additional
price discounts in the near future.
The proportion of patients that would switch to biosimilar
infliximab differed between countries for several reasons. One
reason is that price discounts on biosimilar infliximab varied
between countries; in France prices for biosimilar infliximab
and reference infliximab were equal, whereas in Italy a price
discount of 25% applied. The availability of biosimilar infliximab
particularly changes market shares for reference infliximab, but
also for other available products. To obtain savings, the total
cost of biosimilar infliximab would have to be cheaper than
other alternatives if provided to naïve patients prior to other
alternatives. The increasing budget for AS in the UK and
France and for CD and UC in France showed that the current
price discounts used in those countries are not sufficient to
ensure budget savings. Scenario analyses 1 and 2 show that
larger discounts would result in budget savings for all countries.
Apparently, physicians are price sensitive, as larger discounts
would lead to higher proportions of patients to receive biosimilar
infliximab. However, their price sensitivity is limited, as the
majority of patients would be switched only if large discounts are
in place. Physicians’ price sensitivity is also related to national
policies, which can stimulate the use of biosimilars in various
ways. For instance, specific regulation is installed in Norway
to increase the uptake of biosimilars, amongst which biosimilar
infliximab, and reduce biosimilar prices substantially (Jahnsen
and Kaasen Jorgensen, 2017).
Other reasons include physicians’ beliefs about the
comparability of biosimilars to reference products. There
are strict regulations about comparability of biosimilars
(Simoens et al., 2012), but still not all physicians in our
sample believed that biosimilar infliximab was perfectly
comparable to the reference product. As a result, they might
be less inclined to switch patients from reference product to
biosimilar.
Limitations
The study was based on input from a Delphi survey conducted
in 2015. Since then, several developments have taken place that
need to be taken into account when interpreting the results
from our study. In addition to Inflectra R© and Remsima R©,
another biosimilar infliximab (marketed as Flixabi R©) is now
becoming available in European countries. Also, the uptake of
biosimilar products since then has exceeded expectations, which
can be attributed to various reasons. Firstly, actual discounts
on prices have been larger than presented to the respondents
of the Delphi panel. Secondly, specialists are more willing to
prescribe biosimilars. This was recently found in a survey among
IBD specialists, performed by ECCO (Danese et al., 2016). The
specialists state that they have less concerns and more confidence
in the use of biosimilars than was previously the case. National
rheumatology guidelines in the UK, Germany, and Belgium
include guidance to prescribe biosimilar products (Dörner et al.,
2016). Another development that has been observed since the
Delphi survey was conducted, is that other biosimilars have
entered the market, such as biosimilar etanercept. Scenario five
showed that the introduction of biosimilar etanercept would lead
to budget savings. Many more biosimilars are in the pipeline
for RA and IBD (Dörner and Kay, 2015; Dörner et al., 2016).
When these will reach the market, this could lead to competition
and pressure on prices of biosimilars and innovator products,
as we see already happening. As a result, a larger proportion of
patients are expected to be treated with biosimilars, as was shown
in scenarios 1 and 2, leading to larger savings.
The coefficient of variation was used to assess the dispersion
of respondents’ answers. Differences in answers were particularly
prominent with respect to the expected percentage of naïve
patients to receive biosimilar infliximab and the percentage of
existing patients to switch from other treatments to biosimilar
infliximab. For this reason, median values were used in the study
(rather than mean values), to prevent that the effect of outliers on
the values used in the model would be too big. For rheumatology,
although at least one respondent per country was included in
the sample, the number of respondents was deemed too small to
calculate country-specific values. Therefore, answers for the five
countries were aggregated to one EU5 average. Epidemiological
data and input parameters regarding costs used in themodel were
country-specific. Whether responses from experts in the Delphi
survey were representative of their country could not be assess.
However, variation between experts participating in the study
was limited, suggesting that their answers were representative.
Price changes for existing therapies were neglected in the
study. In reality, prices of existing products might be lowered
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FIGURE 6 | Budget impact of adopting biosimilar infliximab for rheumatology per country, base case.
FIGURE 7 | Budget impact of adopting biosimilar infliximab for gastroenterology per country, base case (including vedolizumab for Germany and United Kingdom).
if competition increases with the entry of other (biosimilar)
products. Furthermore, the study did not take into account
possible market access agreements e.g., discounts on list prices or
other risk sharing agreements. As a result, the current estimates of
budget savings might be overestimated and increases in spending
might be underestimated.
We assumed that no vial sharing occurred in order to ensure
comparability of resource use and drug acquisition costs between
countries, although in practice vial sharing may occur. However,
this practice is variable and likely to differ between countries and
between hospitals within a country. As data on vial sharing are
not widely available and may not be generalizable, we preferred
to assume that no vial sharing occurred in our analysis.
Vedolizumab was included in the base case as a treatment
option for CD and UC in the UK and Germany to adequately
reflect the available treatments in these countries. However,
this complicates the assessment of the impact of biosimilar
infliximab on the budget in these countries, as the impact on
the budget of biosimilar infliximab and vedolizumab could not
be disentangled. If the price of vedolizumab was set equal to the
price of biosimilar infliximab, savings in the budget were shown
for the UK and Germany, resembling observations for Spain and
Italy. Likewise, the budgets in France, Spain, and Italy, increased
when vedolizumab was assumed to be available in these countries
as well, as shown in scenario 4.
Other Studies
Various studies have investigated the impact of biosimilars on
healthcare budgets. Our results deviate from earlier, assumption-
based predictions on the impact of biosimilar infliximab on
healthcare budgets that projected budget savings for various
European countries in both rheumatology and gastroenterology
(McCarthy et al., 2013; Brodszky et al., 2014; Jha et al., 2014;
Kim et al., 2014). The approach in these studies particularly
varied from our methodology using an (arbitrary) value for
the price reductions of biosimilar infliximab, instead of using
discounts as provided in national list prices. In the scenario
analyses, we showed that our model also projects savings when
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TABLE 4 | Budget impact of adopting biosimilar infliximab: scenario findings (including vedolizumab for Germany and United Kingdom).
Year 1 Year 2 Year 3 Year 4 Year 5
BASE CASE ANALYSES
Rheumatology
UK e 109,774 e −361,574 e −1,516,193 e −2,357,542 e −3,015,846
Germany e −443,784 e −1,116,306 e −1,549,699 e −1,852,230 e −2,126,358
France e 183,796 e 426,298 e 537,628 e 814,764 e 1,280,851
Spain e −228,679 e −507,376 e −603,453 e −648,025 e −689,832
Italy e −1,225,796 e −2,595,818 e −2,870,381 e −3,149,564 e −3,526,855
Gastroenterology
UK e 30,779,344 e 61,960,467 e 62,872,012 e 63,797,046 e 64,604,315
Germany e 7,420,414 e 14,728,780 e 14,681,882 e 14,752,677 e 15,020,780
France e 104,251 e 320,745 e 513,850 e 670,798 e 870,614
Spain e −283,165 e −870,727 e −1,480,663 e −2,089,845 e −2,695,510
Italy e −1,174,462 e −2,526,173 e −2,940,214 e −3,411,692 e −3,882,665
SCENARIO 1: PRICE OF BIOSIMILAR INFLIXIMAB DISCOUNTED FOR 50% OF REFERENCE INFLIXIMAB
Rheumatology
UK e −15,826,272 e −53,769,047 e −57,183,780 e −60,482,707 e −63,457,253
Germany e −43,782,381 e −89,078,802 e −92,058,868 e −94,918,717 e −97,649,974
France e −9,206,659 e −18,834,298 e −19,742,566 e −20,715,955 e −21,671,071
Spain e −17,360,235 e −35,112,377 e −35,975,255 e −36,910,978 e −37,821,201
Italy e −38,149,588 e −76,982,705 e −78,411,624 e −79,892,237 e −81,347,278
Gastroenterology
UK e −113,570,922 e −230,027,142 e −235,708,347 e −241,213,559 e −246,548,274
Germany e −44,684,033 e −93,146,186 e −101,855,520 e −111,336,722 e −120,801,286
France e −43,764,760 e −89,661,347 e −95,017,107 e −98,776,518 e −100,307,928
Spain e −8,167,878 e −17,126,717 e −18,693,461 e −20,213,632 e −21,664,256
Italy e −3,148,046 e −6,891,950 e −8,496,980 e −10,310,860 e −11,985,143
SCENARIO 2: PRICE OF BIOSIMILAR INFLIXIMAB DISCOUNTED FOR 75% OF REFERENCE INFLIXIMAB
Rheumatology
UK e −56,764,286 e −156,181,784 e −162,511,019 e −168,329,708 e −173,636,759
Germany e −132,789,823 e −269,178,624 e −276,530,199 e −283,256,605 e −289,091,903
France e −28,402,716 e −58,242,592 e −61,179,770 e −63,899,217 e −66,273,865
Spain e −53,320,545 e −107,952,297 e −110,680,098 e −113,124,434 e −115,128,116
Italy e −96,307,582 e −194,685,762 e −198,971,950 e −202,979,944 e −206,531,593
Gastroenterology
UK e −150,569,509 e −306,944,642 e −318,021,207 e −328,753,872 e −339,153,401
Germany e −108,085,499 e −221,495,452 e −233,517,906 e −245,875,301 e −256,555,585
France e −118,182,220 e −234,622,649 e −232,142,716 e −230,935,187 e −230,239,289
Spain e −21,806,068 e −44,673,440 e −46,878,688 e −49,140,862 e −51,314,227
Italy e −8,495,706 e −18,275,388 e −20,380,916 e −22,207,043 e −24,321,345
SCENARIO 3: ADDITIONAL CLINICAL TRIAL/OBSERVATIONAL STUDIES EVIDENCE FOR CD AND UC
UK e 20,363,034 e 40,691,058 e 40,641,188 e 40,687,784 e 40,787,204
Germany e 8,737,610 e 16,588,897 e 15,038,121 e 13,880,180 e 13,732,601
France e 1,422,850 e 3,226,728 e 3,682,854 e 3,897,423 e 4,173,502
Spain e −2,010,138 e −4,305,483 e −4,901,324 e −5,542,733 e −6,203,693
Italy e −3,953,058 e −8,050,072 e −8,362,715 e −8,669,219 e −8,955,885
SCENARIO 4: VEDOLIZUMAB AVAILABLE IN ALL EU5 MARKETS FOR CD AND UC
UK e 30,779,344 e 61,960,467 e 62,872,012 e 63,797,046 e 64,604,315
Germany e 7,420,414 e 14,728,780 e 14,681,882 e 14,752,677 e 15,020,780
France e 29,772,322 e 60,125,991 e 61,304,358 e 62,625,004 e 64,247,075
Spain e 1,988,848 e 3,739,724 e 3,398,922 e 3,269,710 e 3,223,687
Italy e 2,398,784 e 4,472,121 e 3,865,715 e 3,439,909 e 3,150,509
(Continued)
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TABLE 4 | Continued
Year 1 Year 2 Year 3 Year 4 Year 5
SCENARIO 5: ETANERCEPT BIOSIMILAR AVAILABLE FOR RA AND AS
UK e 109,774 e −1,444,700 e −3,927,167 e −5,254,046 e −6,403,037
Germany e −443,784 e −6,512,964 e −13,809,565 e −17,023,432 e −20,251,333
France e 183,796 e 168,252 e −167,228 e −274,849 e −192,770
Spain e −228,679 e −2,997,140 e −6,236,275 e −7,622,321 e −9,033,152
Italy e −1,225,796 e −6,966,839 e −12,859,449 e −15,679,125 e −18,678,506
SCENARIO 6: RITUXIMAB BIOSIMILAR AVAILABLE FOR RA
UK e 109,774 e −1,870,365 e −5,208,772 e −7,372,658 e −9,299,708
Germany e −443,784 e −3,556,527 e −7,531,251 e −9,992,568 e −12,340,330
France e 183,796 e 181,972 e −41,939 e 55,407 e 345,741
Spain e −228,679 e −1,193,487 e −2,120,955 e −2,453,371 e −2,777,641
Italy e −1,225,796 e −3,379,697 e −4,738,065 e −5,607,527 e −6,556,249
larger discounts were used. Importantly, our results for UK and
Germany also deviate because of the inclusion of vedolizumab in
our study, associated with a large increase in the budget.
Scenario 5 in our study, investigating the impact of the
introduction of a biosimilar for etanercept, resembled the
findings of an decreasing budget also found in an earlier study
investigating budget impact in EU5 countries (Ruff et al., 2015).
Implications
The number of biosimilars in the pipeline to replace the biologic
treatmens in rheumatology and gastroenterology is very large
(Dörner and Kay, 2015; Dörner et al., 2016), and underlines
both the importance of this study and the opportunity for policy
makers to obtain reductions in healthcare budgets. When these
biosimilar products will reach the market, it is likely that this
will result in downward pressure on prices of all biological
treatments, leading to discounts that are larger than the ones
used in this study. Besides, list prices, as used in the base case
analyses, probably do not reflect actual price levels of biosimilar
infliximab, as confidential price agreements were not included in
the analyses. Although further research, using updated prices and
treatment options and including (confidential) price agreements,
is needed to establish the actual budget impact of adopting
biosimilar infliximab, scenario 1, using a price discount of 50% on
biosimilar infliximab, is in our opinion likely to reflect the actual
budget impact of biosimilar infliximab better than the base case
analyses.
The purpose of introducing biosimilars is to constrain the
growing financial impact of expensive biologic treatments and/or
to expand access to healthcare. In our study, the introduction of
biosimilar infliximab would lead to increasing budgets in some
countries instead and would only lead to modest savings in other
countries. In scenario analyses 1 and 2, we have shown that when
price discounts are large enough physicians will be more prone
to change their prescribing behavior and then budgetary savings
will occur. Policy makers should therefore focus on substantial
price reductions for biosimilar products. Furthermore, our study
showed that the proportion of patients to be switched from
reference infliximab to biosimilar infliximab is limited (0–10%).
Policy makers can increase budgetary savings by stimulating
transition from reference biologics to biosimilar products. In this
respect, policy makers, and prescribers should be made aware
of the fact that biosimilar products are as safe and effective as
reference products, but that they come at a lower price.
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